



Omico.

Cancer  
meets its match



# SUMMARY REPORT

# Australian Precision Oncology Symposium (APOS) 26

Friday 6 & Saturday 7 March 2026,  
UNSW Kensington



# Event Summary

APOS 26 focused on **‘Mainstreaming Precision Oncology: Transforming Care Through Science, Medicine and Equity’**—diving into the precision oncology revolution that is reshaping cancer care—and its shift from the margins of innovation into the mainstream. The event featured leading local and international speakers, offering a range of perspectives on the latest developments in the field.

The program featured five sessions spanning breakthrough therapies, workforce and technology integration, precision-guided care in the germline setting, and the promise of genomics for cancers of unknown primary and underserved populations. A live molecular oncology board rounded out the agenda, showcasing how precision oncology is being applied in real time to guide patient care.



## 317 Attendees

In person and virtual, including oncology professionals - clinicians, researchers, life science industry representatives, advocates, and policymakers.



## 22 Speakers

# Thank you to our Scientific Committee

This year's program has been guided by our inaugural Scientific Committee, whose combined expertise has shaped a rigorous and relevant agenda grounded in science, medicine, and equity.



**Prof David Thomas**

(Chair)



**Dr Alexandra Jolley**



**Dr Damien Kee**



**A/Prof Mandy Ballinger**



**Dr Maya Kansara**



**Dr Milita Zaheed**



**Dr Min Li Huang**



**Dr Sam Harris**

# APOS 26 Program

## Friday 6 March 2026 (Day 1)

### Session 1: Clinical Trials - Chair: Dr Damien Kee

1:00 - 1:10pm	Welcome and Opening Remarks, <i>Prof David Thomas</i> Acknowledgement of Country
1:10 - 1:45pm	Defining Immunosensitive Cancers, <i>Prof David Thomas</i>
1:45 - 2:05pm	MoST-ASPIRATION, <i>Dr Tony Mersiades</i>
2:05 - 2:25pm	MoST-PANCREAS, <i>Prof David Goldstein</i>
2:25 - 2:45pm	Update on the LUMOS-2 study: A Precision Oncology Trial for Patients with Relapsed IDH Mutant Gliomas, <i>Prof Hui Gan</i>
2:45pm	Afternoon Tea Break

### Session 2: Emerging Technology - Chair: Dr Alexandra Jolley

3:15 - 3:50pm	Molecular Second Opinions, <i>Prof Sean Grimmond</i>
3:50 - 4:10pm	Homologous Recombination Assays in Precision Oncology, <i>Prof Anna Brown, Dr John Grady</i>
4:10 - 4:30pm	Mass Spec-based Proteomics in Precision Oncology, <i>Dr Ned McNamee</i>
4:30 - 4:50pm	ADCs in Practice: IHC Workup and Implementation, <i>Dr Min Li Huang</i>
4:50 - 5:20pm	Panel: Making It Happen — Preparing the Workforce to Mainstream Precision Oncology, <i>Dr Greg Gaughran, Prof Paul James, Dr Milita Zaheed, Dr Sam Harris, Dr Sara Wahlroos, Prof David Goldstein, Prof Natalie Taylor</i>
5:20 - 5:30pm	Day 1: Evaluation and Close, <i>Ian Black</i>

## Saturday 7 March 2026 (Day 2)

### Session 3: The rising significance of risk in cancer care - Chair: A/Prof Mandy Ballinger

9:00 - 9:05am	Opening Remarks, <i>A/Prof Mandy Ballinger</i>
9:05 - 9:45am	Mainstreaming Innovations: Lessons from NICE, <i>Steve Williamson</i>
9:45 - 10:10am	Implementing Polygenic Risk Scores in Breast Cancer, <i>Prof Paul James</i>
10:10 - 10:35am	The Growing Opportunity for Germline Genetics in Cancer, <i>Dr Milita Zaheed</i>
10:35am	Morning tea break

### Session 4: Leave No-One Behind - Chair: Dr Sam Harris

11:05 - 11:30am	Advancing Genomic Medicine with First Nations Communities: From Blood Group Research to Precision Oncology, <i>Prof Maree Toombs</i>
11:30 - 11:50am	Now It's Personal: Precision medicine as a Tool for Equity, <i>Christine Cockburn</i>
11:50am - 12:10pm	Regional vs Urban: Understanding Variation in Omico's CaSP Uptake and Conversion, <i>Dr Sam Harris</i>
12:10 - 12:30pm	Q & A / Panel, <i>Prof Maree Toombs, Christine Cockburn, A/Prof Mei Ling Yap</i>
12:30pm	Lunch

### Session 5: Live Molecular Oncology Board - CUP Focused - Chair: Prof David Thomas

1:30 - 2:30pm	Open mic: Individual Cases from Molecular Pathology to Treatment Recommendations, <i>Dr Alexandra Jolley, Dr Sam Harris, Dr Damien Kee, Dr Milita Zaheed, Dr John Grady, Dr Min Li Huang</i>
2:30 - 2:45pm	APOS 26 Close, <i>Prof David Thomas &amp; Ian Black</i>

# Thank you to our valued sponsors

We sincerely appreciate the generous support and active involvement of our **12 sponsors** who played a key role in the success of APOS 26.

## Gold Sponsors



## Silver Sponsors



## Bronze Sponsors



# Social Media Impact



## 16,133 Impressions

On content posted on Omico social media channels.



*\*Number does not include impressions from shared content.*

25 Posts

441 Reactions

36 Mentions & Reposts

## #APOS26



# Delegate Feedback

The following results were obtained post-event via online and in person surveys out of a total of 76 responses - **Average scores out of 10.**

## 8.7

How educational did you find the content of APOS 26?

## 8.5

APOS 26 provided me with insights that I can share with my colleagues

## 9.3

How likely would it be that you attend a similar educational meeting if offered in the future?

## 8.8

Symposium Format

## 8.4

Venue

## 9.1

Organisation of Symposium

“Another very well executed APOS. Congratulations!

“Great community and keen to keep in touch.

“What an amazing conference. My first attendance and I just loved it! Will be back every year.

“Very informative!

“Well run, covered wide range of topics.


“I was online but I enjoyed the format—where you see the presenter and the slides—I felt I was there. It was my first one and I am already looking at the next year one. It was informative but not overloaded.



# APOS 26 Recordings

APOS 26 presentation recordings are available on the Omico website, where speakers have provided consent.

[View APOS 26 presentations](#)







# Contact

Should you have any questions or require further information, please contact:

**Leah Wishart - Marketing Manager, Omico**  
**Hilmer Building (E10), Union Rd, UNSW**  
**Kensington, NSW, 2052**  
**Email: [apos@omico.org.au](mailto:apos@omico.org.au)**

**omico.org.au**    **#APOS26**

©Copyright 2026. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not for profit company limited by guarantee. Hilmer building (E10), Union Rd, UNSW, Kensington, NSW, 2052.



Cancer  
meets its match

